Peter Doshi, associate editor of the medical journal BMJ, and Eric Topol, Scripps Research professor of molecular medicine, wrote a devastating NY Times opinion piece about the COVID vaccine clinical trials.

They exposed the fatal flaw in the large Pfizer, AstraZeneca, and Moderna trials.

September 22, the Times: "These Coronavirus Trials Don't Answer the One Question We Need to Know":

"If you were to approve a coronavirus vaccine, would you approve one that you only knew protected people only from the most mild form of Covid-19, or one that would prevent its serious complications?"

"The answer is obvious. You would want to protect against the worst cases."

"But that's not how the companies testing three of the leading coronavirus vaccine candidates, Moderna, Pfizer and AstraZeneca, whose U.S. trial is on hold, are approaching the problem."

"According to the protocols for their studies, which they released late last week, a vaccine could meet the companies' benchmark for success if it lowered the risk of mild Covid-19, but was never shown to reduce moderate or severe forms of the disease, or the risk of hospitalization, admissions to the intensive care unit or death."

"To say a vaccine works should mean that most people no longer run the risk of getting seriously sick. That's not what these trials will determine."